These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 7530588

  • 1. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
    Storm FK, Gilchrist KW, Warner TF, Mahvi DM.
    Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL.
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [Abstract] [Full Text] [Related]

  • 3. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Sep; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M, Ondrias F, Muy-Kheng T, Kastner M, Singer Ch, Pohlodek K.
    Bratisl Lek Listy; 2014 Sep; 115(7):445-51. PubMed ID: 25077370
    [Abstract] [Full Text] [Related]

  • 8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Sep; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 9. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, Lu P.
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB.
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
    Wan D, Zhang Y, Yu Q, Li F, Zhuo J.
    Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.